布拉氏酵母对肺炎继发腹泻患儿的辅助治疗效果及对肠道菌群和免疫功能的影响  

Efficacy of adjuvant therapy with Saccharomyces boulardii in children with diarrhoea secondary to pneumonia and its effect on intestinal flora and immune function

作　　者：钱颖[1] 俞静云 QIAN Ying;YU Jingyun(Department of Pediatrics,Jinhua People's Hospital,Jinhua,Zhejiang 321000,China)

机构地区：[1]金华市人民医院儿科,浙江321000

出　　处：《中国微生态学杂志》2023年第12期1439-1443,共5页Chinese Journal of Microecology

摘　　要：目的探究布拉氏酵母辅助治疗肺炎继发腹泻患儿的疗效及对肠道菌群和免疫功能的影响,以明确布拉氏酵母的干预效果。方法以便利抽样法选取本院收治的128例肺炎继发腹泻患儿作为研究对象,随机分为对照组(64例)和辅助治疗组(64例)。其中对照组患儿给予蒙脱石散治疗,辅助治疗组给予布拉氏酵母辅助治疗。比较两组患儿治疗效果,免疫球蛋白(IgM、IgG、IgA)、T淋巴细胞亚群(CD3+、CD4+、CD8+)水平,肠道菌群及不良反应发生情况。结果辅助治疗组患儿住院时间[(5.31±0.53)d]、止泻时间[(3.15±0.32)d]、退热时间[(1.25±0.15)d]、大便次数恢复正常时间[(3.56±0.36)d]均显著低于对照组[(7.45±0.75)d、(4.36±0.45)d、(2.46±0.25)d、(4.11±0.40)d](均P<0.05)。辅助治疗组患儿治疗后外周血IgM、IgG、IgA、CD3+细胞、CD4+细胞、肠球菌属、乳杆菌属、CD8+细胞、真杆菌属数量和水平分别为(1.52±0.17)g/L、(15.36±1.57)g/L、(1.85±0.25)g/L、(58.37±5.86)%、(40.57±4.12)%、(12.53±1.25)lgCFU/g、(10.68±1.08)lg CFU/g、(18.42±1.86)%、(2.80±0.28)lg CFU/g,对照组分别为(1.23±0.13)g/L、(12.43±1.26)g/L、(1.42±0.15)g/L、(51.24±5.15)%、(36.78±3.71)%、(11.05±1.12)lgCFU/g、(9.23±0.95)lgCFU/g、(21.64±2.18)%、(3.27±0.33)lg CFU/g,与治疗前比较,差异均有统计学意义(均P<0.05);且两组治疗后组间比较差异均有统计学意义(均P<0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论布拉氏酵母菌辅助治疗肺炎继发腹泻患儿可有效提高免疫功能,改善肠道微生态,缩短治疗时间,安全有效。Objective To observe the efficacy of Saccharomyces boulardii in the adjuvant treatment of diarrhea secondary to pneumonia and its effect on intestinal flora and immune function in children,and clarify the intervention effect of Saccharomyces boulardii.Methods A total of 128 children with diarrhea secondary to pneumonia admitted to our hospital were selected by convenient sampling method,and randomly divided into control group(64 cases)and adjuvant treatment group(64 cases).The control group was treated with montmorillonite powder,while the adjuvant treatment group was given adjuvant therapy with Saccharomyces boulardii.The treatment effects,immunoglobulins(IgM,IgG,IgA),T lymphocyte subsets(CD3+,CD4+,CD8+),intestinal microecology and adverse reactions were compared between groups.Results The hospitalization stay,time to diarrhea disappearance,time to defervescence,and time to recovery of normal stool frequency in the adjuvant treatment group were(5.31±0.53)days,(3.15±0.32)days,(1.25±0.15)days and(3.56±0.36)days respectively,significantly lower than those in the control group[(7.45±0.75)days,(4.36±0.45)days,(2.46±0.25)days,(4.11±0.40)days].After treatment,the peripheral blood IgM,IgG,IgA,CD3+,CD4+,Enterococcus,Lactobacillus,CD8+and Eubacterium in adjuvant therapy group were(1.52±0.17)g/L,(15.36±1.57)g/L,(1.85±0.25)g/L,(58.37±5.86)%,(40.57±4.12)%,(12.53±1.25)lg CFU/g,(10.68±1.08)lg CFU/g,(18.42±1.86)%and(2.80±0.28)lg CFU/g,while those in control group were(1.23±0.13)g/L,(12.43±1.26)g/L,(1.42±0.15)g/L,(51.24±5.15)%,(36.78±3.71)%,(11.05±1.12)lg CFU/g,(9.23±0.95)lg CFU/g,(21.64±2.18)%and(3.27±0.33)lg CFU/g,significantly different from those before treatment,respectively;there were significant difference between the two groups after treatment(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The adjuvant treatment with Saccharomyces boulardii in children with diarrhea secondary to pneumonia can effectively improve imm

关 键 词：肺炎 继发腹泻 布拉氏酵母 辅助治疗 肠道微生态 

分 类 号：R725[医药卫生—儿科]